Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.

@article{Wu2019InflammatoryBC,
  title={Inflammatory breast cancer outcomes by breast cancer subtype: a population-based study.},
  author={San-Gang Wu and Wen-wen Zhang and J. Wang and Yong Dong and Jia-yuan Sun and Yong-Xiong Chen and Zhen-Yu He},
  journal={Future oncology},
  year={2019},
  volume={15 5},
  pages={
          507-516
        }
}
AIM To assess the outcomes of breast cancer subtype in inflammatory breast cancer (IBC). METHODS We retrospectively assessed IBC patients from the SEER program. RESULTS We identified 626 patients, including 230 (36.7%),100 (17.6%), 113 (18.1%), and 173 (27.6%) patients with HoR+/HER2-, HoR+/HER2+, HoR-/HER2+, and HoR-/HER2- subtype disease, respectively. Multivariate analysis demonstrated that, using HoR+/HER2- subtype as reference, patients with HoR+/HER2+ subtype had better breast cancer… Expand
Update on systemic treatment for newly diagnosed inflammatory breast cancer
...
1
2
...

References

SHOWING 1-10 OF 34 REFERENCES
Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
  • H. Masuda, T. Brewer, +13 authors N. Ueno
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2014
...
1
2
3
4
...